Absci · 公司檔案

公開已核驗進展

1. Absci 公布 AI 设计抗体 ABS-201 的 II 期试验初步计划

   Thu Sep 24 2026 12:00:49 GMT+0000 (Coordinated Universal Time) · 1 條當前公開證據

   据 Absci 官方公告，AI 设计抗体 ABS-201 的 II 期试验预计于 2027 年中启动。当前披露为初步计划，不能写成 II 期已经开展。

   Absci

   核查事件證據 →

合作、許可與並購時間線

當前顯示的公開進展中沒有合作、許可或並購節點；這不代表該公司從未發生相關活動。

以上來自最新 1 條已核驗進展。合作事件成立與模型效果、實驗結果或臨床進度分別需要證據。

公開原文線索

• Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis

  Absci official news RSS · 行業原文收錄 · 來源發佈：Thu Sep 24 2026 12:00:49 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:07:26 GMT+0000 (Coordinated Universal Time)

  Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER

  原始出處

• Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026

  Absci official news RSS · 行業原文收錄 · 來源發佈：Tue Jul 14 2026 20:05:30 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:07:26 GMT+0000 (Coordinated Universal Time)

  VANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announc

  原始出處

• Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)

  Absci official news RSS · 行業原文收錄 · 來源發佈：Wed Jun 24 2026 10:30:27 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:07:26 GMT+0000 (Coordinated Universal Time)

  Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval o

  原始出處

• Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026

  Absci official news RSS · 行業原文收錄 · 來源發佈：Thu Apr 23 2026 20:04:58 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:07:26 GMT+0000 (Coordinated Universal Time)

  VANCOUVER, Wash. and NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announ

  原始出處

已驗證的官方與訂閱來源

• Absci official news RSS · 採集已啓用 · 最近成功 Fri Oct 09 2026 07:07:44 GMT+0000 (Coordinated Universal Time)

來源驗證與持續採集分別顯示；原文收錄不自動成為已核驗事件。